17,850 Shares in Danaher Co. (NYSE:DHR) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new stake in shares of Danaher Co. (NYSE:DHR - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 17,850 shares of the conglomerate's stock, valued at approximately $4,963,000.

Several other institutional investors have also recently made changes to their positions in the company. nVerses Capital LLC bought a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the second quarter valued at $25,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the third quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the 3rd quarter worth about $40,000. Finally, FSA Wealth Management LLC purchased a new position in Danaher in the 3rd quarter worth about $50,000. Institutional investors own 79.05% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. StockNews.com lowered shares of Danaher from a "buy" rating to a "hold" rating in a research report on Thursday. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a research report on Wednesday, October 23rd. Raymond James cut their price target on Danaher from $310.00 to $300.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. UBS Group lowered their price objective on shares of Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. Finally, Stephens restated an "overweight" rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and a consensus target price of $287.16.

Danaher Stock Performance

NYSE:DHR traded up $5.78 during mid-day trading on Monday, hitting $235.91. The company's stock had a trading volume of 2,625,253 shares, compared to its average volume of 2,779,061. The business's fifty day moving average is $249.91 and its two-hundred day moving average is $258.14. The stock has a market cap of $170.39 billion, a price-to-earnings ratio of 45.02, a PEG ratio of 4.23 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $217.96 and a 1 year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the company earned $2.02 earnings per share. Danaher's revenue for the quarter was up 3.1% compared to the same quarter last year. Analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend was Friday, September 27th. Danaher's dividend payout ratio (DPR) is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.